Linzess 0.25mg tablet sydd for treatment of chronic constipation

recent days, Astellas and IronwoodPharmaceutical(the company(jointly announced that Linzess (Linalotide, Linalotide) 0.25mg tablet has been approved by Japanese regulators for the treatment of chronic constipation (chro
nic constipation, CC)Linzes0.25mg tablets are licensed from Ironwood and are responsible for the development and commercialization of the Japanese market by Astellasthe Japanese market, Linzess was approved in December 2016 as the first prescription drug for constipation-type irritability syndrome (IBS-C) and was launched in Japan in March 2017The studythis approval is based on data from a Phase III clinical study conducted in adult patients with chronic constipation in JapanThe study was a double-blind, placebo-controlled Phase III study that enrolled 186 adult patients with chronic constipationIn the study, patients were randomly assigned to Linzess (0.5 mg) or placebo for 4 weeks at a ratio of 1:1data showed a statistically significant improvement in the Linzess treatment group at the primary endpoint (changes in the average spontaneous bowel course frequency from baseline) at the primary endpoint (the average spontaneous bowel course in week 1 of treatment) compared to the placebo groupThe most common adverse events in the study were diarrhea, both mild or moderateThe most common adverse reaction in the study was diarrhea, and all cases were mild or moderateabout linaclotide
linaclotide is a bird nucleotide cyclase-C (GC-C) agonist that binds to and localizes GC-C receptors that act on the surface of the epithelial tube cavity of the small intestineThe activation of GC-C leads to an increase in intracellular and extracellular cyclophosphate (cGMP) concentrations The elevation of cGMP in the cell stimulates the secretion of chlorine and bicarbonate ions into the intestinal cavity, causing the small intestine secretion to increase and accelerate passage animal models, linaclotide also showed a role in reducing small intestine pain, which is thought to be mediated by an increase in extracellular cGMP that reduces the activity of the intestinal pain-sensing nerve, thus inducing visceral pain reduction in the U.S market, Linaclotide is jointly commercialized by Ironwood and AlJian under the brand name Linzess, which is used in adult IBS-C and chronic isophation (CIC) treatments in Europe, Linaclotide is commercialized by El Jian, under the brand name Constella, which is used to treat severe IBS-C In Japan, Astellas has exclusive development and commercialization rights to linaclotide in addition Ironwood has entered into a partnership agreement with AstraZeneca to promote the development and commercialization of Linaclotide in Greater China